Core Insights - Curanex Pharmaceuticals Inc. has appointed two experienced life sciences experts, Dr. Daniel Pascheles and Dr. Nicholas A. Meanwell, to its Scientific Advisory Board, bringing over 75 years of combined pharmaceutical experience, including 50 years at major companies like Merck & Co. and Bristol Myers Squibb [2][8] Group 1: New Appointments - Dr. Daniel Pascheles has over 25 years of experience in building competitive intelligence organizations within global life sciences companies and has held senior roles at Merck & Co. and Aventis [3][4] - Dr. Nicholas A. Meanwell is a distinguished medicinal chemist with four decades at Bristol Myers Squibb, where he led programs in various therapeutic areas and advanced 33 clinical candidates [6][7] Group 2: Company Focus and Product Development - Curanex is focused on discovering and developing botanical drugs for inflammatory diseases, with its lead candidate, Phyto-N, showing proven anti-inflammatory properties and a long history of human use in China [9][10] - Phyto-N has demonstrated effects in animal models for six inflammatory diseases and is primarily focused on moderate to severe ulcerative colitis, with Phase I clinical trials expected to start in Q4 2026 [10]